Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

s issued by Angiotech or to include such information in documents required to be filed with the applicable United States or Canadian securities regulatory authorities or otherwise make such information publicly available.

The projections and other forward looking financial information found herein were not, when made, and are not, historical facts but are forward looking statements about the objectives, strategies, financial conditions, results of operations and businesses of Angiotech and its subsidiaries and are subject to important risks, uncertainties and assumptions.  The forward looking statements and projections set out in this press release are, in the case of Angiotech's Base Medical Products and Proprietary Medical Products businesses, based upon Angiotech's reasonable estimates, assumptions and expectations about these businesses and the markets in which Angiotech operates at the time such information was prepared, or in the case of Angiotech's Royalty business, are derived based upon certain publicly available information, including analyst reports and other sources, regarding expectations for certain products, in particular for sales of paclitaxel-eluting stents by certain of our partners from which we derive or expect to derive royalty revenue pursuant to intellectual property licensing agreements with those partners.  In each case, such projections or forward looking statements are subject to significant business, economic, competitive and other uncertainties and contingencies (including those set out under the heading "Risk Factors" contained in Angiotech's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in Angiotech's most recent Form 10-Q and Management's Discussion and Analysis for the six months ended June 30, 2010), which are beyond Angiotech's or our partners' control.

In addition, forward looking statements reflect numerous assumptions by Angiotech and industry analysts with respect to fu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... London (PRWEB) May 28, 2015 ... Computer Aided Engineering software, announced today it is ... (PSRI). CD-adapco will provide state-of-the-art engineering simulation tools ... share their expertise and experiences in analyzing particle ... industry members and advance the understanding of flow ...
(Date:5/28/2015)... 28, 2015 Global futurist and ... to ask his audiences if they are ready ... robotics, solar cells, fuel cells, rapid health care ... battery storage technology, driverless cars, artificial intelligence masquerading ... inexpensive online education. , While the majority ...
(Date:5/28/2015)... Cambridge, MA (PRWEB) May 28, 2015 ... provider located in Basel, Switzerland, and the ... (ACRES), a Cambridge, Massachusetts-based non-profit organization operating ... building a global system to enhance quality, ... product development and health research, are pleased ...
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) ... Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... seems to dominate the breast cancer monoclonal antibody ... molecule, Herceptin has been able to dominate this ... breast cancer cells become recalcitrant and relapsed condition ...
Breaking Biology Technology:CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
... GeneGo, Inc., the leading systems biology tools company, ... GeneGo Center of Excellence. Burnham researchers will have ... training and advanced support. The Burnham institute ... OMICs experimental studies throughout many departments, including research ...
... 2 NicOx S.A.,(NYSE Euronext Paris: COX) ... with,DSM for the commercial manufacture and supply ... ingredient). Naproxcinod is NicOx, lead,investigational product and ... (CINOD) class of,anti-inflammatory agents, which recently achieved ...
... 2 Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer ... from severe angina, today announced the addition of veteran medical ... Cohen as a member of the Company,s Board of Directors, ... , Mr. Cohen, 49, has over ...
Cached Biology Technology:The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... ham radio, amateur astronomy, and early computing? Well, ... 2,000 people from around the world belong to the ... fuel cells, low-cost lab equipment, environmental surveillance, personal bio-monitoring, ... Project at the Woodrow Wilson Center is partnering with ...
... a consortium of universities and companies headed by biologists at ... three years to conduct basic research that will pave the ... alternative to gasoline for our nation,s transportation fuel. The ... million from a consortium of biotechnology and energy companies, providing ...
... is available in Spanish . Health conscious ... good choice when it comes to preparing meals and dipping ... the Agricultural Research Service (ARS), has found that phenolic components ... the inflammatory response. The researchers knew from other studies ...
Cached Biology News:DOE awards UC San Diego consortium $9 million for algal biofuels research 2Molecular biology provides clues to health benefits of olive oil 2